Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody –cytotoxic drug conjugate
ConclusionsT-DM1 exhibited preclinical activity in HER2-overexpressing BTC. Further evaluation in clinical studies is warranted.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Bile Duct Cancer | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Cholangiocarcinoma | Drugs & Pharmacology | Fish | Gallbladder Cancer | HER2 | Herceptin | Study